{"gene":"ALK","run_date":"2026-06-09T22:02:43","timeline":{"discoveries":[{"year":2002,"finding":"NPM-ALK (nucleophosmin-anaplastic lymphoma kinase) fusion protein constitutively activates Stat3 through direct phosphorylation; ALK also binds and activates Jak3, but Jak3 is not required for Stat3 activation or in vitro transformation. Constitutive Stat3 activation by NPM-ALK upregulates Bcl-xL transcription, providing anti-apoptotic signals that protect cells from death.","method":"Transfection of wild-type and kinase-inactive NPM-ALK K210R mutant into BaF3 cells; immunohistochemistry on primary human ALCLs; inhibitor studies (Jak/Stat pathway inhibitors); functional rescue assays","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal functional experiments with kinase-dead mutant, inhibitor studies, and primary human tissue validation across multiple orthogonal methods","pmids":["11850821"],"is_preprint":false},{"year":2000,"finding":"In inflammatory myofibroblastic tumors, tropomyosin (TPM3 and TPM4) N-terminal coiled-coil domains fuse to the ALK C-terminal kinase domain, producing ~95 kDa fusion oncoproteins with constitutive kinase activity and tyrosine phosphorylation. The subcellular localization of ALK fusion proteins depends on the localization of the fusion partner.","method":"Molecular cloning of fusion genes; Western blotting demonstrating ~95 kDa proteins; in vitro kinase assays demonstrating constitutive activity; immunohistochemistry correlating ALK localization with fusion partner identity","journal":"The American Journal of Pathology","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct molecular cloning, in vitro kinase assay demonstrating constitutive activity, replicated across multiple tumor specimens","pmids":["10934142"],"is_preprint":false},{"year":2010,"finding":"NPM-ALK and TPM3-ALK oncoproteins are sufficient to induce lymphoma/leukemia (early B-cell arrest and lymphomagenesis) in vivo in conditional transgenic mice and are required for tumor maintenance; inactivation of the ALK oncogene by doxycycline or pharmacological ALK inhibition (PF-2341066) causes sustained tumor regression.","method":"Conditional transgenic mouse models (tetracycline-inducible expression under EmuSRα promoter); doxycycline-mediated oncogene inactivation; treatment with specific ALK inhibitor PF-2341066 in vivo","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo genetic epistasis with conditional transgenic system and pharmacological validation, replicated for two different ALK fusions","pmids":["20223922"],"is_preprint":false},{"year":2010,"finding":"NPM-ALK constitutively activates Stat3, which binds to the HIF1α gene promoter and drives HIF1α mRNA transcription under normoxia. NPM-ALK-induced HIF1α expression requires the enzymatic activity of NPM-ALK and is mediated through Stat3; HIF1α in turn suppresses mTORC1 activation and regulates VEGF synthesis.","method":"BaF3 cells transfected with wild-type and kinase-inactive NPM-ALK K210R mutant; ALK inhibitor treatment of ALK+ TCL cells; chromatin immunoprecipitation (ChIP) demonstrating Stat3 binding to HIF1α promoter; siRNA-mediated depletion of STAT3 and HIF1α","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1 / Strong — kinase-dead mutant, ChIP, siRNA knockdown, and inhibitor studies across multiple orthogonal methods in a single study","pmids":["21102525"],"is_preprint":false},{"year":2012,"finding":"Different EML4-ALK fusion variants (v1, v2, v3a, v3b) exhibit differential sensitivity to ALK kinase inhibitors (crizotinib, TAE684) that correlates with differences in protein stability. Sensitivity to HSP90 inhibition also varies by fusion partner and differs from ALK inhibitor sensitivity patterns. Combining ALK and HSP90 inhibitors results in synergistic cytotoxicity.","method":"Ba/F3 cell line model expressing different EML4-ALK variants; cytotoxicity assays; intracellular localization studies; protein stability measurements; HSP90 inhibitor combination studies","journal":"Clinical Cancer Research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean cell-based functional assays with multiple fusion variants and two structurally diverse inhibitors, single lab","pmids":["22912387"],"is_preprint":false},{"year":2011,"finding":"Resistance to ALK tyrosine kinase inhibitors arises via two mechanisms: (1) a secondary L1152R ALK kinase domain mutation that confers resistance to both crizotinib and TAE684, and (2) coactivation of EGFR signaling as a bypass pathway independent of ALK mutation. Dual inhibition of both ALK and EGFR is the most effective therapeutic strategy for cells with either resistance mechanism.","method":"Sequencing of resistant tumor biopsy and resistant cell line derived from a crizotinib-treated patient; generation of TAE684-resistant H3122 cell line (TR3); pharmacological combination studies with ALK and EGFR inhibitors","journal":"Cancer Research","confidence":"High","confidence_rationale":"Tier 2 / Strong — resistance mutation identified from patient biopsy and independently validated in cell line model with two orthogonal resistance mechanisms; dual inhibition functionally validated","pmids":["21791641"],"is_preprint":false},{"year":2014,"finding":"ALK fusion proteins bind to the adaptor insulin receptor substrate 1 (IRS-1), engaging the IGF-1R signaling pathway. IRS-1 knockdown enhances the antitumor effects of ALK inhibitors. In ALK TKI-resistant models, the IGF-1R pathway is activated, and combined ALK and IGF-1R inhibition improves therapeutic efficacy.","method":"Co-immunoprecipitation of ALK fusion proteins with IRS-1; siRNA knockdown of IRS-1; pharmacological combination studies in ALK TKI-resistant models; biopsy analysis from patients progressing on crizotinib","journal":"Nature Medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct binding demonstrated by Co-IP, functional validation with siRNA knockdown, and translational validation in patient biopsies using multiple orthogonal methods","pmids":["25173427"],"is_preprint":false},{"year":2014,"finding":"ALK tyrosine kinase domain mutations in neuroblastoma at three hotspots confer constitutive kinase activation (oncogenic mutations) and show differential sensitivity to crizotinib in vitro. Biochemical and computational analyses distinguish oncogenic from non-oncogenic mutations.","method":"Comprehensive genomic analysis of 1,596 neuroblastoma samples; biochemical assays measuring kinase activity; computational prediction; in vitro crizotinib sensitivity assays","journal":"Cancer Cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — large-scale biochemical characterization with functional validation across many mutation variants, replicated computationally and experimentally","pmids":["25517749"],"is_preprint":false},{"year":2017,"finding":"ALK directly interacts with EGFR to trigger AKT (serine-threonine kinase) phosphorylation and activate IRF3 and NF-κB signaling pathways in monocytes and macrophages, enabling STING-dependent inflammatory responses to cyclic dinucleotides. Genetic disruption of ALK diminishes STING-mediated innate immune responses.","method":"Co-immunoprecipitation demonstrating ALK-EGFR interaction; genetic knockdown/knockout of ALK in monocytes/macrophages; pharmacological and genetic inhibition of the ALK-STING pathway in murine endotoxemia and sepsis models","journal":"Science Translational Medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP for binding, genetic knockout with defined innate immune phenotype, in vivo validation, single lab","pmids":["29046432"],"is_preprint":false},{"year":2020,"finding":"ALK expression in hypothalamic neurons controls energy expenditure via sympathetic control of adipose tissue lipolysis. Genetic deletion of ALK in mice results in thin animals with marked resistance to diet- and leptin-mutation-induced obesity.","method":"GWAS on thin individuals; RNAi-mediated knockdown of Alk in Drosophila (decreased triglyceride levels); genetic deletion of Alk in mice; measurement of energy expenditure and adipose tissue lipolysis","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic deletion with defined metabolic phenotype, replicated across two model organisms (Drosophila and mouse) with multiple metabolic measurements","pmids":["32442405"],"is_preprint":false},{"year":2016,"finding":"ALK fusions found in inflammatory myofibroblastic tumors (conventional and atypical) include TPM3/4-ALK, DCTN1-ALK, TFG-ALK, RANBP2-ALK, and a novel RRBP1-ALK fusion. RRBP1-ALK shows cytoplasmic ALK expression with perinuclear accentuation (distinct from the nuclear membranous pattern of RANBP2-ALK), demonstrating that fusion partner identity determines subcellular localization of ALK oncoprotein.","method":"ALK immunoprecipitation from tumor lysates; electrophoresis; mass spectrometry characterization of ALK fusion partners; immunohistochemistry for ALK localization","journal":"The Journal of Pathology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — ALK immunoprecipitation combined with mass spectrometry for partner identification and IHC for subcellular localization in a single rigorous study","pmids":["27874193"],"is_preprint":false},{"year":2022,"finding":"PTPN1 and PTPN2 phosphatases bind to ALK and regulate its phosphorylation and activity. Oncogenic ALK and STAT3 repress PTPN1 transcription (creating a feedback loop). PTPN1 is also a phosphatase for SHP2, a key mediator of oncogenic ALK signaling. Loss of PTPN1 or PTPN2 induces ALK TKI resistance by hyperactivating SHP2, MAPK, and JAK/STAT pathways.","method":"Genomic loss-of-function screens; Co-immunoprecipitation demonstrating PTPN1/PTPN2 binding to ALK; phosphatase activity assays; in vitro and in vivo resistance models; RNA sequencing of patient samples with TKI resistance; pharmacological combination of crizotinib with SHP2 inhibitor","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1 / Strong — genome-wide screen, Co-IP for binding, phosphatase activity assays, in vivo validation, and patient sample validation across multiple orthogonal methods","pmids":["34657149"],"is_preprint":false},{"year":2010,"finding":"The SEC31A-ALK fusion transforms IL3-dependent Ba/F3 cells to growth factor independence, and the ALK inhibitor TAE-684 reduces cell proliferation and kinase activity of SEC31A-ALK and its downstream effectors ERK1/2, AKT, STAT3, and STAT5.","method":"Ba/F3 cell transformation assay; pharmacological inhibition with TAE-684; measurement of downstream effector phosphorylation (ERK1/2, AKT, STAT3, STAT5)","journal":"Haematologica","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional transformation assay with pathway analysis using inhibitor, single lab","pmids":["20207848"],"is_preprint":false},{"year":2018,"finding":"ALK signaling in neuroblastoma leads to phosphorylation of ATR and CHK1, supporting an effective DNA damage response. Combined ALK/ATR inhibition results in robust and sustained tumor response, whereas ATR inhibition alone yields initial response followed by relapse. The sustained response to combined inhibition reflects differentiation of tumor cells toward neuronal/Schwann cell lineage identity.","method":"Genetically modified mouse neuroblastoma models; biochemical measurement of ATR and CHK1 phosphorylation downstream of ALK signaling; in vivo treatment with ALK inhibitor, ATR inhibitor, and combination; lineage marker analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo mouse models with biochemical mechanistic validation, single lab","pmids":["38154064"],"is_preprint":false},{"year":2021,"finding":"ALKAL2 ligand overexpression drives ALK TKI-sensitive neuroblastoma in the absence of ALK mutation in mice, demonstrating that ligand-mediated (paracrine/autocrine) ALK activation is sufficient for neuroblastoma development and progression.","method":"Transgenic mouse model with ALKAL2 overexpression; ALK TKI treatment of resulting tumors; comparison with ALK mutation-driven models","journal":"The EMBO Journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic in vivo model with pharmacological validation, single lab","pmids":["33411331"],"is_preprint":false},{"year":2015,"finding":"ALK inhibitor resistance in ALK(F1174L)-driven neuroblastoma is associated with overexpression and activation of the AXL tyrosine kinase and epithelial-to-mesenchymal transition (EMT). AXL phosphorylation confers resistance through upregulated ERK signaling. AXL activation is mediated through increased expression of its ligand GAS6, which also stabilizes the AXL protein. AXL overexpression (but not TWIST2 overexpression alone) induces ALK inhibitor resistance.","method":"Generation of TAE684/LDK378-resistant neuroblastoma cell lines; Western blotting for AXL and downstream signaling; AXL inhibition studies; ectopic overexpression of AXL and TWIST2; GAS6 ligand analysis; HSP90 inhibitor studies","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic dissection with multiple orthogonal approaches (overexpression, inhibition, ligand analysis), single lab","pmids":["26616860"],"is_preprint":false},{"year":2018,"finding":"ALK positively regulates transcriptional expression of MYC and activates c-MYC transactivation of c-MYC target genes in ALK-positive NSCLC. MYCBP was identified as a determinant of crizotinib response by genome-wide shRNA screen, and inhibition of MYC by RNAi or small molecules sensitizes ALK+ cells to crizotinib.","method":"Whole-genome shRNA loss-of-function screen; RNAi knockdown of MYC; small-molecule MYC inhibition; transcriptional analysis of MYC target genes following ALK inhibition","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genome-wide screen with functional validation using two orthogonal approaches (RNAi and small molecule), single lab","pmids":["29507657"],"is_preprint":false},{"year":2021,"finding":"Pharmacological inhibition of ALK (by crizotinib or ceritinib) in ALK-positive ALCL induces immunogenic cell death (ICD), characterized by calreticulin surface exposure, ATP release, HMGB1 release, and type I interferon response. This ICD induction is on-target: it is mimicked by ALK knockdown, lost with resistance-conferring ALK mutants, and replicated by inhibiting downstream ALK signaling pathways. In vivo, ceritinib-treated ALK+ ALCL cells vaccinated immunocompetent mice and protected against rechallenge in an antigen-specific manner.","method":"ICD marker assays (calreticulin exposure, ATP/HMGB1 release); ALK siRNA knockdown; resistance-conferring ALK mutant cell lines; in vivo vaccination/rechallenge experiments in immunocompetent vs. immunodeficient mice; PD-1 blockade combination","journal":"Cell Death & Disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple ICD readouts, genetic validation with knockdown and mutants, in vivo immunological validation, single lab","pmids":["34272360"],"is_preprint":false},{"year":2023,"finding":"ALK inhibitors upregulate ALK expression on neuroblastoma cell surfaces while impairing tumor growth, thereby facilitating the activity of ALK-targeted CAR-T cells. The combination of ALK inhibitors with ALK.CAR-T cells shows potent efficacy specifically against neuroblastoma with low ALK expression, whereas neither modality alone is sufficient.","method":"ALK.CAR-T cell development and testing in vitro and in vivo; flow cytometry for ALK surface expression after inhibitor treatment; combination efficacy studies in neuroblastoma xenograft models","journal":"Cancer Cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic in vivo and in vitro studies demonstrating ALK inhibitor-induced antigen upregulation as the basis for combination synergy, single lab","pmids":["38039964"],"is_preprint":false},{"year":2018,"finding":"PROTAC molecules (TD-004) composed of ceritinib (ALK inhibitor) linked to a VHL E3 ligase ligand effectively induce ALK fusion protein (NPM-ALK and EML4-ALK) degradation via the ubiquitin-proteasome system, inhibit growth of ALK fusion-positive cell lines, and significantly reduce tumor growth in H3122 xenograft models.","method":"PROTAC molecule design and synthesis; cell-based ALK degradation assays in SU-DHL-1 and H3122 cells; xenograft tumor growth assay","journal":"Biochemical and Biophysical Research Communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct protein degradation demonstrated in cells and in vivo with on-target mechanistic attribution via VHL-dependent pathway, single lab","pmids":["30274779"],"is_preprint":false}],"current_model":"ALK is a receptor tyrosine kinase that, when activated via oncogenic fusions (e.g., NPM-ALK, EML4-ALK, TPM3/4-ALK) driven by dimerization through the N-terminal fusion partner, constitutively signals through multiple pathways including JAK/STAT3 (upregulating anti-apoptotic Bcl-xL and HIF1α), Ras/MEK/ERK, PI3K/AKT, and MYC; its subcellular localization is determined by the fusion partner, it directly binds IRS-1 to engage IGF-1R signaling and interacts with EGFR to activate AKT/IRF3/NF-κB in innate immune contexts, while the phosphatases PTPN1/PTPN2 restrain its activity by directly dephosphorylating ALK; in the nervous system, ALK is activated by ALKAL2 ligand and controls energy expenditure through hypothalamic neurons regulating adipose lipolysis, and in neuroblastoma it primes the DNA damage response via ATR/CHK1 phosphorylation."},"narrative":{"mechanistic_narrative":"ALK is a receptor tyrosine kinase that drives oncogenic transformation when its C-terminal kinase domain is fused to N-terminal partners that supply dimerization motifs, generating constitutively active fusion oncoproteins whose subcellular localization is dictated by the fusion partner [PMID:10934142, PMID:27874193]. In anaplastic large cell lymphoma and related malignancies, fusion proteins such as NPM-ALK, TPM3/4-ALK, and SEC31A-ALK signal through STAT3, ERK1/2, AKT, and STAT5; STAT3 activation is kinase-dependent and transcriptionally upregulates anti-apoptotic Bcl-xL and, via direct promoter binding, HIF1α [PMID:11850821, PMID:21102525, PMID:20207848]. These fusions are sufficient to initiate and are required to maintain tumors, since genetic or pharmacological ALK inactivation drives sustained regression [PMID:20223922]. ALK signaling also engages additional effectors: it binds the adaptor IRS-1 to couple into the IGF-1R pathway [PMID:25173427], positively regulates MYC transcription and transactivation [PMID:29507657], and its activity is restrained by the phosphatases PTPN1 and PTPN2, which directly bind and dephosphorylate ALK and limit SHP2-driven downstream signaling [PMID:34657149]. Beyond fusion-driven cancers, point mutations in the ALK kinase domain constitutively activate the receptor in neuroblastoma [PMID:25517749], where ligand-mediated activation by ALKAL2 is itself sufficient to drive tumorigenesis [PMID:33411331] and ALK signaling supports an ATR/CHK1 DNA damage response [PMID:38154064]. ALK additionally has non-oncogenic physiological and immune roles: it interacts with EGFR to activate AKT/IRF3/NF-κB and STING-dependent innate immunity in monocytes and macrophages [PMID:29046432], and hypothalamic ALK controls energy expenditure and adipose lipolysis, with its loss conferring resistance to obesity [PMID:32442405]. Resistance to ALK kinase inhibitors arises through secondary kinase-domain mutations, bypass activation of EGFR, IGF-1R, or AXL signaling, and loss of restraining phosphatases [PMID:21791641, PMID:25173427, PMID:34657149, PMID:26616860].","teleology":[{"year":2000,"claim":"Established that ALK becomes oncogenic by fusion of its kinase domain to partner-derived coiled-coil domains, generating constitutively active proteins whose localization tracks the partner.","evidence":"Molecular cloning, Western blot, and in vitro kinase assays of TPM3/4-ALK fusions in inflammatory myofibroblastic tumors","pmids":["10934142"],"confidence":"High","gaps":["Did not define the full downstream signaling cascade","Limited to a single tumor type"]},{"year":2002,"claim":"Resolved how fusion ALK signals for survival by showing kinase-dependent direct STAT3 phosphorylation upregulates anti-apoptotic Bcl-xL.","evidence":"Wild-type vs kinase-dead NPM-ALK K210R in BaF3 cells, inhibitor studies, and ALCL tissue immunohistochemistry","pmids":["11850821"],"confidence":"High","gaps":["Jak3 binding observed but dispensable, leaving the kinase upstream of STAT3 undefined","Did not address other parallel pathways"]},{"year":2010,"claim":"Demonstrated ALK fusions are both sufficient to initiate and required to maintain lymphoma, validating ALK as a therapeutic target.","evidence":"Conditional doxycycline-inducible transgenic mice with NPM-ALK and TPM3-ALK plus PF-2341066 inhibition","pmids":["20223922"],"confidence":"High","gaps":["Did not test fusion partners beyond NPM and TPM3","Mechanism of regression not dissected at signaling level"]},{"year":2010,"claim":"Extended ALK fusion signaling to transcriptional control of HIF1α via STAT3 binding to its promoter under normoxia.","evidence":"Kinase-dead mutant, ChIP, and STAT3/HIF1α siRNA in BaF3 and ALK+ TCL cells","pmids":["21102525"],"confidence":"High","gaps":["Functional consequence of HIF1α-mediated mTORC1 suppression in vivo not established"]},{"year":2010,"claim":"Showed additional fusions (SEC31A-ALK) transform cells and converge on ERK/AKT/STAT3/STAT5 effectors.","evidence":"Ba/F3 transformation assay with TAE-684 inhibition and downstream phospho-profiling","pmids":["20207848"],"confidence":"Medium","gaps":["Single cell-line model","No in vivo confirmation"]},{"year":2011,"claim":"Defined two mechanisms of acquired resistance: a secondary kinase-domain mutation (L1152R) and EGFR bypass signaling, and showed dual inhibition overcomes both.","evidence":"Sequencing of patient-derived and engineered resistant cell lines with ALK/EGFR combination studies","pmids":["21791641"],"confidence":"High","gaps":["Prevalence of each mechanism in patients not quantified","Other bypass pathways not surveyed"]},{"year":2012,"claim":"Linked EML4-ALK fusion variant identity to differential inhibitor and HSP90 sensitivity through protein stability differences.","evidence":"Ba/F3 lines expressing v1/v2/v3a/v3b with cytotoxicity, localization, stability, and HSP90 combination assays","pmids":["22912387"],"confidence":"Medium","gaps":["Single lab","Clinical correlation of variant-specific sensitivity not established"]},{"year":2014,"claim":"Identified IRS-1 as a direct ALK fusion partner coupling ALK to IGF-1R signaling and an inhibitor resistance pathway.","evidence":"Co-IP, IRS-1 siRNA, ALK/IGF-1R combination in resistant models, and patient biopsies","pmids":["25173427"],"confidence":"High","gaps":["Reciprocal validation of binding limited","Stoichiometry of IRS-1 engagement unknown"]},{"year":2014,"claim":"Distinguished oncogenic from non-oncogenic ALK kinase-domain mutations in neuroblastoma and tied them to differential crizotinib sensitivity.","evidence":"Genomic analysis of 1,596 neuroblastomas with biochemical kinase activity and crizotinib assays","pmids":["25517749"],"confidence":"High","gaps":["Structural basis of inhibitor resistance per mutation not fully resolved"]},{"year":2015,"claim":"Showed AXL/GAS6-driven EMT as a bypass resistance mechanism in ALK(F1174L) neuroblastoma.","evidence":"Resistant cell lines, AXL/TWIST2 overexpression, AXL inhibition, and GAS6 analysis","pmids":["26616860"],"confidence":"Medium","gaps":["Single lab","In vivo and patient confirmation of AXL resistance limited"]},{"year":2016,"claim":"Cataloged diverse IMT fusion partners and reinforced that partner identity dictates ALK subcellular localization.","evidence":"ALK immunoprecipitation, mass spectrometry partner identification, and IHC localization including novel RRBP1-ALK","pmids":["27874193"],"confidence":"High","gaps":["Functional signaling differences between localization patterns not tested"]},{"year":2017,"claim":"Revealed a non-oncogenic immune role: ALK interacts with EGFR to drive AKT/IRF3/NF-κB and STING-dependent innate immunity.","evidence":"Co-IP, ALK knockdown/knockout in monocytes/macrophages, and murine endotoxemia/sepsis models","pmids":["29046432"],"confidence":"Medium","gaps":["Single lab","Direct ALK-EGFR binding not reciprocally validated","Ligand or activation trigger in immune cells undefined"]},{"year":2018,"claim":"Placed MYC downstream of ALK as a transcriptional effector and crizotinib-response determinant in NSCLC.","evidence":"Whole-genome shRNA screen, MYC RNAi and small-molecule inhibition, and MYC target transcriptional analysis","pmids":["29507657"],"confidence":"Medium","gaps":["Single lab","Direct vs indirect transcriptional regulation not separated"]},{"year":2018,"claim":"Connected ALK signaling to the DNA damage response via ATR/CHK1 phosphorylation and showed combined ALK/ATR inhibition drives lineage differentiation.","evidence":"Genetically modified mouse neuroblastoma models with biochemical phospho-readouts and lineage marker analysis","pmids":["38154064"],"confidence":"Medium","gaps":["Single lab","Direct vs indirect ATR phosphorylation not resolved"]},{"year":2018,"claim":"Demonstrated ALK fusion proteins can be eliminated by PROTAC-induced VHL-dependent degradation rather than catalytic inhibition.","evidence":"Ceritinib-VHL PROTAC (TD-004) degradation assays in SU-DHL-1/H3122 cells and H3122 xenografts","pmids":["30274779"],"confidence":"Medium","gaps":["Single lab","Activity against resistant kinase-domain mutants not shown"]},{"year":2020,"claim":"Defined a physiological role for ALK in hypothalamic control of energy expenditure and adipose lipolysis.","evidence":"GWAS in thin individuals, Drosophila RNAi, and Alk-deleted mice with energy expenditure and lipolysis measurements","pmids":["32442405"],"confidence":"High","gaps":["Endogenous ligand and downstream neuronal circuitry not fully mapped"]},{"year":2021,"claim":"Showed ligand-mediated ALK activation by ALKAL2 is sufficient to drive neuroblastoma without ALK mutation.","evidence":"ALKAL2-overexpressing transgenic mice with ALK TKI treatment","pmids":["33411331"],"confidence":"Medium","gaps":["Single lab","Relative contribution of autocrine vs paracrine ALKAL2 not resolved"]},{"year":2021,"claim":"Established that ALK inhibition induces immunogenic cell death on-target in ALK+ ALCL, linking ALK targeting to anti-tumor immunity.","evidence":"ICD marker assays, ALK siRNA, resistance mutants, and in vivo vaccination/rechallenge in immunocompetent mice","pmids":["34272360"],"confidence":"Medium","gaps":["Single lab","Generalizability beyond ALCL not tested"]},{"year":2022,"claim":"Identified PTPN1/PTPN2 as direct ALK-binding phosphatases that restrain ALK and whose loss drives TKI resistance via SHP2 hyperactivation.","evidence":"Genome-wide LOF screens, Co-IP, phosphatase assays, in vivo resistance models, patient RNA-seq, and SHP2 inhibitor combination","pmids":["34657149"],"confidence":"High","gaps":["Direct dephosphorylation site mapping on ALK incomplete"]},{"year":2023,"claim":"Showed ALK inhibitors upregulate surface ALK to enable ALK-targeted CAR-T efficacy against low-expression neuroblastoma.","evidence":"ALK.CAR-T development, flow cytometry for surface ALK after inhibitor treatment, and xenograft combination studies","pmids":["38039964"],"confidence":"Medium","gaps":["Single lab","Mechanism of inhibitor-induced surface upregulation undefined"]},{"year":null,"claim":"The structural basis by which ALKAL2 ligand and partner-driven dimerization activate the wild-type ALK ectodomain, and how endogenous ALK signaling is regulated across its physiological versus oncogenic contexts, remains incompletely defined.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model of ligand-bound full-length receptor in the corpus","Endogenous ALK signaling outputs in normal neurons not mechanistically mapped"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,1,3,11]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,1,7,12]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[9,14]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[9,18]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[1,10]},{"term_id":"GO:0005635","term_label":"nuclear envelope","supporting_discovery_ids":[10]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,3,6,8,12]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[1,2,5,7,10]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[8,17]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[9]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[3,16]}],"complexes":[],"partners":["IRS-1","EGFR","PTPN1","PTPN2","STAT3","ALKAL2","SHP2"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9UM73","full_name":"ALK tyrosine kinase receptor","aliases":["Anaplastic lymphoma kinase"],"length_aa":1620,"mass_kda":176.4,"function":"Neuronal receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis and differentiation of the nervous system (PubMed:11121404, PubMed:11387242, PubMed:16317043, PubMed:17274988, PubMed:30061385, PubMed:34646012, PubMed:34819673). Also acts as a key thinness protein involved in the resistance to weight gain: in hypothalamic neurons, controls energy expenditure acting as a negative regulator of white adipose tissue lipolysis and sympathetic tone to fine-tune energy homeostasis (By similarity). Following activation by ALKAL2 ligand at the cell surface, transduces an extracellular signal into an intracellular response (PubMed:30061385, PubMed:33411331, PubMed:34646012, PubMed:34819673). In contrast, ALKAL1 is not a potent physiological ligand for ALK (PubMed:34646012). Ligand-binding to the extracellular domain induces tyrosine kinase activation, leading to activation of the mitogen-activated protein kinase (MAPK) pathway (PubMed:34819673). Phosphorylates almost exclusively at the first tyrosine of the Y-x-x-x-Y-Y motif (PubMed:15226403, PubMed:16878150). Induces tyrosine phosphorylation of CBL, FRS2, IRS1 and SHC1, as well as of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1 (PubMed:15226403, PubMed:16878150). ALK activation may also be regulated by pleiotrophin (PTN) and midkine (MDK) (PubMed:11278720, PubMed:11809760, PubMed:12107166, PubMed:12122009). PTN-binding induces MAPK pathway activation, which is important for the anti-apoptotic signaling of PTN and regulation of cell proliferation (PubMed:11278720, PubMed:11809760, PubMed:12107166). MDK-binding induces phosphorylation of the ALK target insulin receptor substrate (IRS1), activates mitogen-activated protein kinases (MAPKs) and PI3-kinase, resulting also in cell proliferation induction (PubMed:12122009). Drives NF-kappa-B activation, probably through IRS1 and the activation of the AKT serine/threonine kinase (PubMed:15226403, PubMed:16878150). Recruitment of IRS1 to activated ALK and the activation of NF-kappa-B are essential for the autocrine growth and survival signaling of MDK (PubMed:15226403, PubMed:16878150). May function as regulator of gastric epithelial differentiation (By similarity)","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/Q9UM73/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ALK","classification":"Not Classified","n_dependent_lines":8,"n_total_lines":1208,"dependency_fraction":0.006622516556291391},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ALK","total_profiled":1310},"omim":[{"mim_id":"619746","title":"ZINC FINGER C3HC-TYPE DOMAIN-CONTAINING PROTEIN 1; ZC3HC1","url":"https://www.omim.org/entry/619746"},{"mim_id":"619671","title":"ALK AND LTK LIGAND 2; ALKAL2","url":"https://www.omim.org/entry/619671"},{"mim_id":"619670","title":"ALK AND LTK LIGAND 1; ALKAL1","url":"https://www.omim.org/entry/619670"},{"mim_id":"617626","title":"FIBROMATOSIS, GINGIVAL, 5; GINGF5","url":"https://www.omim.org/entry/617626"},{"mim_id":"617313","title":"SH2 DOMAIN-CONTAINING ADAPTOR PROTEIN F; SHF","url":"https://www.omim.org/entry/617313"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Plasma membrane","reliability":"Supported"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"brain","ntpm":1.9},{"tissue":"pituitary gland","ntpm":2.4},{"tissue":"testis","ntpm":1.5}],"url":"https://www.proteinatlas.org/search/ALK"},"hgnc":{"alias_symbol":["CD246","ALK1"],"prev_symbol":[]},"alphafold":{"accession":"Q9UM73","domains":[{"cath_id":"-","chopping":"51-74_85-103_120-223","consensus_level":"medium","plddt":65.0519,"start":51,"end":223},{"cath_id":"2.60.120.200","chopping":"265-298_317-424","consensus_level":"high","plddt":73.4956,"start":265,"end":424},{"cath_id":"2.60.120.200","chopping":"479-509_517-633","consensus_level":"high","plddt":78.7905,"start":479,"end":633},{"cath_id":"-","chopping":"683-983","consensus_level":"high","plddt":86.2396,"start":683,"end":983},{"cath_id":"2.10.25,2.10.25","chopping":"986-1024","consensus_level":"medium","plddt":73.7292,"start":986,"end":1024},{"cath_id":"3.30.200.20","chopping":"1084-1199","consensus_level":"medium","plddt":77.6657,"start":1084,"end":1199},{"cath_id":"1.10.510.10","chopping":"1203-1283_1290-1404","consensus_level":"medium","plddt":86.9626,"start":1203,"end":1404}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9UM73","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9UM73-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9UM73-F1-predicted_aligned_error_v6.png","plddt_mean":68.19},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ALK","jax_strain_url":"https://www.jax.org/strain/search?query=ALK"},"sequence":{"accession":"Q9UM73","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9UM73.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9UM73/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9UM73"}},"corpus_meta":[{"pmid":"22327623","id":"PMC_22327623","title":"RET, ROS1 and ALK fusions in lung cancer.","date":"2012","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22327623","citation_count":1068,"is_preprint":false},{"pmid":"18594010","id":"PMC_18594010","title":"EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.","date":"2008","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/18594010","citation_count":839,"is_preprint":false},{"pmid":"22080568","id":"PMC_22080568","title":"Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas.","date":"2011","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/22080568","citation_count":749,"is_preprint":false},{"pmid":"10934142","id":"PMC_10934142","title":"TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors.","date":"2000","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/10934142","citation_count":534,"is_preprint":false},{"pmid":"21791641","id":"PMC_21791641","title":"A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.","date":"2011","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/21791641","citation_count":510,"is_preprint":false},{"pmid":"10194450","id":"PMC_10194450","title":"ALK+ lymphoma: clinico-pathological findings and outcome.","date":"1999","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/10194450","citation_count":456,"is_preprint":false},{"pmid":"28122866","id":"PMC_28122866","title":"Targeting ALK: Precision Medicine Takes on Drug Resistance.","date":"2017","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/28122866","citation_count":422,"is_preprint":false},{"pmid":"11684952","id":"PMC_11684952","title":"Anaplastic lymphoma kinase (ALK) expression in the inflammatory myofibroblastic tumor: a comparative immunohistochemical study.","date":"2001","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/11684952","citation_count":400,"is_preprint":false},{"pmid":"11850821","id":"PMC_11850821","title":"Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death.","date":"2002","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11850821","citation_count":321,"is_preprint":false},{"pmid":"25517749","id":"PMC_25517749","title":"ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma.","date":"2014","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/25517749","citation_count":305,"is_preprint":false},{"pmid":"27573755","id":"PMC_27573755","title":"The role of the ALK receptor in cancer biology.","date":"2016","source":"Annals of oncology : official journal of the European Society for Medical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/27573755","citation_count":284,"is_preprint":false},{"pmid":"25173427","id":"PMC_25173427","title":"Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer.","date":"2014","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25173427","citation_count":241,"is_preprint":false},{"pmid":"23201355","id":"PMC_23201355","title":"Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition.","date":"2012","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/23201355","citation_count":232,"is_preprint":false},{"pmid":"22912387","id":"PMC_22912387","title":"Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants.","date":"2012","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/22912387","citation_count":231,"is_preprint":false},{"pmid":"29636358","id":"PMC_29636358","title":"Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer.","date":"2018","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/29636358","citation_count":216,"is_preprint":false},{"pmid":"11607814","id":"PMC_11607814","title":"Translocations involving anaplastic lymphoma kinase (ALK).","date":"2001","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11607814","citation_count":213,"is_preprint":false},{"pmid":"10793082","id":"PMC_10793082","title":"Expression of the ALK tyrosine kinase gene in neuroblastoma.","date":"2000","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/10793082","citation_count":168,"is_preprint":false},{"pmid":"10552961","id":"PMC_10552961","title":"Lymphomas expressing ALK fusion protein(s) other than NPM-ALK.","date":"1999","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/10552961","citation_count":157,"is_preprint":false},{"pmid":"23931927","id":"PMC_23931927","title":"ALK inhibitors in the treatment of advanced NSCLC.","date":"2013","source":"Cancer treatment reviews","url":"https://pubmed.ncbi.nlm.nih.gov/23931927","citation_count":154,"is_preprint":false},{"pmid":"31358542","id":"PMC_31358542","title":"Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity.","date":"2019","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/31358542","citation_count":129,"is_preprint":false},{"pmid":"34727172","id":"PMC_34727172","title":"ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition.","date":"2022","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/34727172","citation_count":128,"is_preprint":false},{"pmid":"26416997","id":"PMC_26416997","title":"Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma.","date":"2015","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/26416997","citation_count":122,"is_preprint":false},{"pmid":"29046432","id":"PMC_29046432","title":"ALK is a therapeutic target for lethal sepsis.","date":"2017","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29046432","citation_count":114,"is_preprint":false},{"pmid":"29642598","id":"PMC_29642598","title":"ALK in Neuroblastoma: Biological and Therapeutic Implications.","date":"2018","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/29642598","citation_count":112,"is_preprint":false},{"pmid":"26457764","id":"PMC_26457764","title":"Entrectinib: a potent new TRK, ROS1, and ALK inhibitor.","date":"2015","source":"Expert opinion on investigational drugs","url":"https://pubmed.ncbi.nlm.nih.gov/26457764","citation_count":110,"is_preprint":false},{"pmid":"17694547","id":"PMC_17694547","title":"Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy.","date":"2008","source":"Medicinal research reviews","url":"https://pubmed.ncbi.nlm.nih.gov/17694547","citation_count":110,"is_preprint":false},{"pmid":"27874193","id":"PMC_27874193","title":"ALK oncoproteins in atypical inflammatory myofibroblastic tumours: novel RRBP1-ALK fusions in epithelioid inflammatory myofibroblastic sarcoma.","date":"2016","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/27874193","citation_count":107,"is_preprint":false},{"pmid":"30662002","id":"PMC_30662002","title":"Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance.","date":"2019","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/30662002","citation_count":107,"is_preprint":false},{"pmid":"28910456","id":"PMC_28910456","title":"Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma.","date":"2018","source":"JAMA oncology","url":"https://pubmed.ncbi.nlm.nih.gov/28910456","citation_count":104,"is_preprint":false},{"pmid":"34175504","id":"PMC_34175504","title":"Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC.","date":"2021","source":"Lung cancer (Amsterdam, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/34175504","citation_count":103,"is_preprint":false},{"pmid":"30274779","id":"PMC_30274779","title":"Induced protein degradation of anaplastic lymphoma kinase (ALK) by proteolysis targeting chimera (PROTAC).","date":"2018","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/30274779","citation_count":102,"is_preprint":false},{"pmid":"31419130","id":"PMC_31419130","title":"Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK).","date":"2019","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31419130","citation_count":100,"is_preprint":false},{"pmid":"28077299","id":"PMC_28077299","title":"Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers.","date":"2017","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/28077299","citation_count":100,"is_preprint":false},{"pmid":"21504625","id":"PMC_21504625","title":"Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP.","date":"2011","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/21504625","citation_count":98,"is_preprint":false},{"pmid":"25857825","id":"PMC_25857825","title":"ALK rearrangement and overexpression in epithelioid fibrous histiocytoma.","date":"2015","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/25857825","citation_count":98,"is_preprint":false},{"pmid":"26616860","id":"PMC_26616860","title":"ALK inhibitor resistance in ALK(F1174L)-driven neuroblastoma is associated with AXL activation and induction of EMT.","date":"2015","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/26616860","citation_count":96,"is_preprint":false},{"pmid":"22157554","id":"PMC_22157554","title":"Crizotinib and testing for ALK.","date":"2011","source":"Journal of the National Comprehensive Cancer Network : JNCCN","url":"https://pubmed.ncbi.nlm.nih.gov/22157554","citation_count":89,"is_preprint":false},{"pmid":"21945349","id":"PMC_21945349","title":"Emerging importance of ALK in neuroblastoma.","date":"2011","source":"Seminars in cancer biology","url":"https://pubmed.ncbi.nlm.nih.gov/21945349","citation_count":89,"is_preprint":false},{"pmid":"25461779","id":"PMC_25461779","title":"Anaplastic large cell lymphomas: ALK positive, ALK negative, and primary cutaneous.","date":"2015","source":"Advances in anatomic pathology","url":"https://pubmed.ncbi.nlm.nih.gov/25461779","citation_count":86,"is_preprint":false},{"pmid":"33627640","id":"PMC_33627640","title":"Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/33627640","citation_count":83,"is_preprint":false},{"pmid":"24496003","id":"PMC_24496003","title":"HIP1-ALK, a novel ALK fusion variant that responds to crizotinib.","date":"2014","source":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/24496003","citation_count":83,"is_preprint":false},{"pmid":"31366041","id":"PMC_31366041","title":"The Transcriptional Roles of ALK Fusion Proteins in Tumorigenesis.","date":"2019","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/31366041","citation_count":75,"is_preprint":false},{"pmid":"37073562","id":"PMC_37073562","title":"Targeted therapy for lung cancer: Beyond EGFR and ALK.","date":"2023","source":"Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/37073562","citation_count":74,"is_preprint":false},{"pmid":"32442405","id":"PMC_32442405","title":"Identification of ALK in Thinness.","date":"2020","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/32442405","citation_count":72,"is_preprint":false},{"pmid":"30687633","id":"PMC_30687633","title":"ALK Inhibitors in the Treatment of ALK Positive NSCLC.","date":"2019","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/30687633","citation_count":69,"is_preprint":false},{"pmid":"20207848","id":"PMC_20207848","title":"ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions.","date":"2010","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/20207848","citation_count":69,"is_preprint":false},{"pmid":"29286567","id":"PMC_29286567","title":"Crizotinib in ALK+ inflammatory myofibroblastic tumors-Current experience and future perspectives.","date":"2017","source":"Pediatric blood & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/29286567","citation_count":66,"is_preprint":false},{"pmid":"36807339","id":"PMC_36807339","title":"Genomic ALK alterations in primary and relapsed neuroblastoma.","date":"2023","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/36807339","citation_count":58,"is_preprint":false},{"pmid":"30400214","id":"PMC_30400214","title":"Anaplastic Lymphoma Kinase (ALK) Receptor Tyrosine Kinase: A Catalytic Receptor with Many Faces.","date":"2018","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30400214","citation_count":57,"is_preprint":false},{"pmid":"21205076","id":"PMC_21205076","title":"Oncogenic mutations of ALK in neuroblastoma.","date":"2011","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/21205076","citation_count":50,"is_preprint":false},{"pmid":"24589437","id":"PMC_24589437","title":"Prospective screening for ALK: clinical features and outcome according to ALK status.","date":"2014","source":"European journal of cancer (Oxford, England : 1990)","url":"https://pubmed.ncbi.nlm.nih.gov/24589437","citation_count":47,"is_preprint":false},{"pmid":"30789735","id":"PMC_30789735","title":"Designing Dual Inhibitors of Anaplastic Lymphoma Kinase (ALK) and Bromodomain-4 (BRD4) by Tuning Kinase Selectivity.","date":"2019","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30789735","citation_count":47,"is_preprint":false},{"pmid":"22808292","id":"PMC_22808292","title":"ALK-immunoreactive neoplasms.","date":"2012","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/22808292","citation_count":46,"is_preprint":false},{"pmid":"37541389","id":"PMC_37541389","title":"Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations.","date":"2023","source":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/37541389","citation_count":45,"is_preprint":false},{"pmid":"33494549","id":"PMC_33494549","title":"Therapeutic Sequencing in ALK+ NSCLC.","date":"2021","source":"Pharmaceuticals (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/33494549","citation_count":45,"is_preprint":false},{"pmid":"37430060","id":"PMC_37430060","title":"ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer.","date":"2023","source":"Nature cancer","url":"https://pubmed.ncbi.nlm.nih.gov/37430060","citation_count":42,"is_preprint":false},{"pmid":"33411331","id":"PMC_33411331","title":"ALK ligand ALKAL2 potentiates MYCN-driven neuroblastoma in the absence of ALK mutation.","date":"2021","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/33411331","citation_count":42,"is_preprint":false},{"pmid":"38039964","id":"PMC_38039964","title":"ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells.","date":"2023","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/38039964","citation_count":40,"is_preprint":false},{"pmid":"33310890","id":"PMC_33310890","title":"Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK-Rearranged/TP53-Mutant NSCLC via Noxa Expression.","date":"2020","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/33310890","citation_count":40,"is_preprint":false},{"pmid":"34657149","id":"PMC_34657149","title":"Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma.","date":"2022","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/34657149","citation_count":38,"is_preprint":false},{"pmid":"24623980","id":"PMC_24623980","title":"Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer.","date":"2014","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/24623980","citation_count":38,"is_preprint":false},{"pmid":"33273548","id":"PMC_33273548","title":"ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/33273548","citation_count":37,"is_preprint":false},{"pmid":"34036223","id":"PMC_34036223","title":"Impact of ALK Inhibitors in Patients With ALK-Rearranged Nonlung Solid Tumors.","date":"2021","source":"JCO precision oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34036223","citation_count":37,"is_preprint":false},{"pmid":"31334113","id":"PMC_31334113","title":"Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells.","date":"2019","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/31334113","citation_count":37,"is_preprint":false},{"pmid":"30642554","id":"PMC_30642554","title":"Histologic transformation of ALK-rearranged adenocarcinoma to squamous cell carcinoma after treatment with ALK inhibitor.","date":"2018","source":"Lung cancer (Amsterdam, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/30642554","citation_count":36,"is_preprint":false},{"pmid":"31139322","id":"PMC_31139322","title":"Defining molecular risk in ALK+ NSCLC.","date":"2019","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/31139322","citation_count":35,"is_preprint":false},{"pmid":"34125345","id":"PMC_34125345","title":"Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma.","date":"2021","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/34125345","citation_count":35,"is_preprint":false},{"pmid":"29374774","id":"PMC_29374774","title":"The ALK receptor in sympathetic neuron development and neuroblastoma.","date":"2018","source":"Cell and tissue research","url":"https://pubmed.ncbi.nlm.nih.gov/29374774","citation_count":34,"is_preprint":false},{"pmid":"30271189","id":"PMC_30271189","title":"ALK (D5F3) CDx: an immunohistochemistry assay to identify ALK-positive NSCLC patients.","date":"2018","source":"Pharmacogenomics and personalized medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30271189","citation_count":34,"is_preprint":false},{"pmid":"27130468","id":"PMC_27130468","title":"Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non-Small-Cell Lung Cancer: Analysis and Literature Review.","date":"2016","source":"Clinical lung cancer","url":"https://pubmed.ncbi.nlm.nih.gov/27130468","citation_count":33,"is_preprint":false},{"pmid":"34272360","id":"PMC_34272360","title":"Pharmacological inhibitors of anaplastic lymphoma kinase (ALK) induce immunogenic cell death through on-target effects.","date":"2021","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/34272360","citation_count":32,"is_preprint":false},{"pmid":"26654422","id":"PMC_26654422","title":"Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib.","date":"2016","source":"Expert review of anticancer therapy","url":"https://pubmed.ncbi.nlm.nih.gov/26654422","citation_count":32,"is_preprint":false},{"pmid":"12401829","id":"PMC_12401829","title":"Anaplastic lymphoma kinase (ALK) protein expressing lymphoma after liver transplantation: case report and literature review.","date":"2002","source":"Journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/12401829","citation_count":31,"is_preprint":false},{"pmid":"21102525","id":"PMC_21102525","title":"Oncogenic kinase NPM/ALK induces expression of HIF1α mRNA.","date":"2010","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/21102525","citation_count":30,"is_preprint":false},{"pmid":"30518629","id":"PMC_30518629","title":"Discovery and Characterization of Recurrent, Targetable ALK Fusions in Leiomyosarcoma.","date":"2018","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/30518629","citation_count":29,"is_preprint":false},{"pmid":"27637426","id":"PMC_27637426","title":"ALK alterations and inhibition in lung cancer.","date":"2016","source":"Seminars in cancer biology","url":"https://pubmed.ncbi.nlm.nih.gov/27637426","citation_count":28,"is_preprint":false},{"pmid":"37938503","id":"PMC_37938503","title":"Update of Diagnosis and Targeted Therapy for ALK+ Inflammation Myofibroblastic Tumor.","date":"2023","source":"Current treatment options in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/37938503","citation_count":28,"is_preprint":false},{"pmid":"28061468","id":"PMC_28061468","title":"The heterogeneous landscape of ALK negative ALCL.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28061468","citation_count":28,"is_preprint":false},{"pmid":"27468827","id":"PMC_27468827","title":"The renal effects of ALK inhibitors.","date":"2016","source":"Investigational new drugs","url":"https://pubmed.ncbi.nlm.nih.gov/27468827","citation_count":28,"is_preprint":false},{"pmid":"29067644","id":"PMC_29067644","title":"Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor Ceritinib.","date":"2017","source":"Targeted oncology","url":"https://pubmed.ncbi.nlm.nih.gov/29067644","citation_count":27,"is_preprint":false},{"pmid":"35409355","id":"PMC_35409355","title":"Activity of ALK Inhibitors in Renal Cancer with ALK Alterations: A Systematic Review.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35409355","citation_count":26,"is_preprint":false},{"pmid":"28606126","id":"PMC_28606126","title":"Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC.","date":"2017","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/28606126","citation_count":26,"is_preprint":false},{"pmid":"24166094","id":"PMC_24166094","title":"Targeted Therapy for Neuroblastoma: ALK Inhibitors.","date":"2013","source":"Klinische Padiatrie","url":"https://pubmed.ncbi.nlm.nih.gov/24166094","citation_count":26,"is_preprint":false},{"pmid":"20223922","id":"PMC_20223922","title":"Conditional TPM3-ALK and NPM-ALK transgenic mice develop reversible ALK-positive early B-cell lymphoma/leukemia.","date":"2010","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/20223922","citation_count":26,"is_preprint":false},{"pmid":"28359267","id":"PMC_28359267","title":"Aberrant expression of ALK and EZH2 in Merkel cell carcinoma.","date":"2017","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/28359267","citation_count":25,"is_preprint":false},{"pmid":"27662658","id":"PMC_27662658","title":"Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27662658","citation_count":25,"is_preprint":false},{"pmid":"32059449","id":"PMC_32059449","title":"Emerging Roles of ALK in Immunity and Insights for Immunotherapy.","date":"2020","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/32059449","citation_count":24,"is_preprint":false},{"pmid":"30273505","id":"PMC_30273505","title":"CMTR1-ALK: an ALK fusion in a patient with no response to ALK inhibitor crizotinib.","date":"2018","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/30273505","citation_count":24,"is_preprint":false},{"pmid":"28561721","id":"PMC_28561721","title":"Managing Resistance to EFGR- and ALK-Targeted Therapies.","date":"2017","source":"American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting","url":"https://pubmed.ncbi.nlm.nih.gov/28561721","citation_count":23,"is_preprint":false},{"pmid":"29507657","id":"PMC_29507657","title":"ALK is a critical regulator of the MYC-signaling axis in ALK positive lung cancer.","date":"2018","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29507657","citation_count":23,"is_preprint":false},{"pmid":"22506598","id":"PMC_22506598","title":"Detection of anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer and related issues in ALK inhibitor therapy: a literature review.","date":"2012","source":"Molecular diagnosis & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/22506598","citation_count":23,"is_preprint":false},{"pmid":"30791979","id":"PMC_30791979","title":"miR-100-5p confers resistance to ALK tyrosine kinase inhibitors Crizotinib and Lorlatinib in EML4-ALK positive NSCLC.","date":"2019","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/30791979","citation_count":23,"is_preprint":false},{"pmid":"36303600","id":"PMC_36303600","title":"Non-small-cell lung cancer: how to manage ALK-, ROS1- and NTRK-rearranged disease.","date":"2022","source":"Drugs in context","url":"https://pubmed.ncbi.nlm.nih.gov/36303600","citation_count":22,"is_preprint":false},{"pmid":"35042943","id":"PMC_35042943","title":"HER3 activation contributes toward the emergence of ALK inhibitor-tolerant cells in ALK-rearranged lung cancer with mesenchymal features.","date":"2022","source":"NPJ precision oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35042943","citation_count":22,"is_preprint":false},{"pmid":"40055571","id":"PMC_40055571","title":"ALK in cancer: from function to therapeutic targeting.","date":"2025","source":"Nature reviews. Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/40055571","citation_count":19,"is_preprint":false},{"pmid":"33528789","id":"PMC_33528789","title":"Brigatinib: A Review in ALK-Inhibitor Naïve Advanced ALK-Positive NSCLC.","date":"2021","source":"Drugs","url":"https://pubmed.ncbi.nlm.nih.gov/33528789","citation_count":19,"is_preprint":false},{"pmid":"34575503","id":"PMC_34575503","title":"Therapeutic Targeting of the Anaplastic Lymphoma Kinase (ALK) in Neuroblastoma-A Comprehensive Update.","date":"2021","source":"Pharmaceutics","url":"https://pubmed.ncbi.nlm.nih.gov/34575503","citation_count":18,"is_preprint":false},{"pmid":"30857967","id":"PMC_30857967","title":"Fusion of ALK to the melanophilin gene MLPH in pediatric Spitz nevi.","date":"2019","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/30857967","citation_count":17,"is_preprint":false},{"pmid":"27565908","id":"PMC_27565908","title":"De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers.","date":"2016","source":"Lung cancer (Amsterdam, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/27565908","citation_count":17,"is_preprint":false},{"pmid":"38154064","id":"PMC_38154064","title":"ALK signaling primes the DNA damage response sensitizing ALK-driven neuroblastoma to therapeutic ATR inhibition.","date":"2023","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/38154064","citation_count":16,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":48945,"output_tokens":5531,"usd":0.1149,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":14243,"output_tokens":5411,"usd":0.103245,"stage2_stop_reason":"end_turn"},"total_usd":0.218145,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2002,\n      \"finding\": \"NPM-ALK (nucleophosmin-anaplastic lymphoma kinase) fusion protein constitutively activates Stat3 through direct phosphorylation; ALK also binds and activates Jak3, but Jak3 is not required for Stat3 activation or in vitro transformation. Constitutive Stat3 activation by NPM-ALK upregulates Bcl-xL transcription, providing anti-apoptotic signals that protect cells from death.\",\n      \"method\": \"Transfection of wild-type and kinase-inactive NPM-ALK K210R mutant into BaF3 cells; immunohistochemistry on primary human ALCLs; inhibitor studies (Jak/Stat pathway inhibitors); functional rescue assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal functional experiments with kinase-dead mutant, inhibitor studies, and primary human tissue validation across multiple orthogonal methods\",\n      \"pmids\": [\"11850821\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"In inflammatory myofibroblastic tumors, tropomyosin (TPM3 and TPM4) N-terminal coiled-coil domains fuse to the ALK C-terminal kinase domain, producing ~95 kDa fusion oncoproteins with constitutive kinase activity and tyrosine phosphorylation. The subcellular localization of ALK fusion proteins depends on the localization of the fusion partner.\",\n      \"method\": \"Molecular cloning of fusion genes; Western blotting demonstrating ~95 kDa proteins; in vitro kinase assays demonstrating constitutive activity; immunohistochemistry correlating ALK localization with fusion partner identity\",\n      \"journal\": \"The American Journal of Pathology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct molecular cloning, in vitro kinase assay demonstrating constitutive activity, replicated across multiple tumor specimens\",\n      \"pmids\": [\"10934142\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"NPM-ALK and TPM3-ALK oncoproteins are sufficient to induce lymphoma/leukemia (early B-cell arrest and lymphomagenesis) in vivo in conditional transgenic mice and are required for tumor maintenance; inactivation of the ALK oncogene by doxycycline or pharmacological ALK inhibition (PF-2341066) causes sustained tumor regression.\",\n      \"method\": \"Conditional transgenic mouse models (tetracycline-inducible expression under EmuSRα promoter); doxycycline-mediated oncogene inactivation; treatment with specific ALK inhibitor PF-2341066 in vivo\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo genetic epistasis with conditional transgenic system and pharmacological validation, replicated for two different ALK fusions\",\n      \"pmids\": [\"20223922\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"NPM-ALK constitutively activates Stat3, which binds to the HIF1α gene promoter and drives HIF1α mRNA transcription under normoxia. NPM-ALK-induced HIF1α expression requires the enzymatic activity of NPM-ALK and is mediated through Stat3; HIF1α in turn suppresses mTORC1 activation and regulates VEGF synthesis.\",\n      \"method\": \"BaF3 cells transfected with wild-type and kinase-inactive NPM-ALK K210R mutant; ALK inhibitor treatment of ALK+ TCL cells; chromatin immunoprecipitation (ChIP) demonstrating Stat3 binding to HIF1α promoter; siRNA-mediated depletion of STAT3 and HIF1α\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — kinase-dead mutant, ChIP, siRNA knockdown, and inhibitor studies across multiple orthogonal methods in a single study\",\n      \"pmids\": [\"21102525\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Different EML4-ALK fusion variants (v1, v2, v3a, v3b) exhibit differential sensitivity to ALK kinase inhibitors (crizotinib, TAE684) that correlates with differences in protein stability. Sensitivity to HSP90 inhibition also varies by fusion partner and differs from ALK inhibitor sensitivity patterns. Combining ALK and HSP90 inhibitors results in synergistic cytotoxicity.\",\n      \"method\": \"Ba/F3 cell line model expressing different EML4-ALK variants; cytotoxicity assays; intracellular localization studies; protein stability measurements; HSP90 inhibitor combination studies\",\n      \"journal\": \"Clinical Cancer Research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean cell-based functional assays with multiple fusion variants and two structurally diverse inhibitors, single lab\",\n      \"pmids\": [\"22912387\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Resistance to ALK tyrosine kinase inhibitors arises via two mechanisms: (1) a secondary L1152R ALK kinase domain mutation that confers resistance to both crizotinib and TAE684, and (2) coactivation of EGFR signaling as a bypass pathway independent of ALK mutation. Dual inhibition of both ALK and EGFR is the most effective therapeutic strategy for cells with either resistance mechanism.\",\n      \"method\": \"Sequencing of resistant tumor biopsy and resistant cell line derived from a crizotinib-treated patient; generation of TAE684-resistant H3122 cell line (TR3); pharmacological combination studies with ALK and EGFR inhibitors\",\n      \"journal\": \"Cancer Research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — resistance mutation identified from patient biopsy and independently validated in cell line model with two orthogonal resistance mechanisms; dual inhibition functionally validated\",\n      \"pmids\": [\"21791641\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"ALK fusion proteins bind to the adaptor insulin receptor substrate 1 (IRS-1), engaging the IGF-1R signaling pathway. IRS-1 knockdown enhances the antitumor effects of ALK inhibitors. In ALK TKI-resistant models, the IGF-1R pathway is activated, and combined ALK and IGF-1R inhibition improves therapeutic efficacy.\",\n      \"method\": \"Co-immunoprecipitation of ALK fusion proteins with IRS-1; siRNA knockdown of IRS-1; pharmacological combination studies in ALK TKI-resistant models; biopsy analysis from patients progressing on crizotinib\",\n      \"journal\": \"Nature Medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct binding demonstrated by Co-IP, functional validation with siRNA knockdown, and translational validation in patient biopsies using multiple orthogonal methods\",\n      \"pmids\": [\"25173427\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"ALK tyrosine kinase domain mutations in neuroblastoma at three hotspots confer constitutive kinase activation (oncogenic mutations) and show differential sensitivity to crizotinib in vitro. Biochemical and computational analyses distinguish oncogenic from non-oncogenic mutations.\",\n      \"method\": \"Comprehensive genomic analysis of 1,596 neuroblastoma samples; biochemical assays measuring kinase activity; computational prediction; in vitro crizotinib sensitivity assays\",\n      \"journal\": \"Cancer Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — large-scale biochemical characterization with functional validation across many mutation variants, replicated computationally and experimentally\",\n      \"pmids\": [\"25517749\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ALK directly interacts with EGFR to trigger AKT (serine-threonine kinase) phosphorylation and activate IRF3 and NF-κB signaling pathways in monocytes and macrophages, enabling STING-dependent inflammatory responses to cyclic dinucleotides. Genetic disruption of ALK diminishes STING-mediated innate immune responses.\",\n      \"method\": \"Co-immunoprecipitation demonstrating ALK-EGFR interaction; genetic knockdown/knockout of ALK in monocytes/macrophages; pharmacological and genetic inhibition of the ALK-STING pathway in murine endotoxemia and sepsis models\",\n      \"journal\": \"Science Translational Medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP for binding, genetic knockout with defined innate immune phenotype, in vivo validation, single lab\",\n      \"pmids\": [\"29046432\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ALK expression in hypothalamic neurons controls energy expenditure via sympathetic control of adipose tissue lipolysis. Genetic deletion of ALK in mice results in thin animals with marked resistance to diet- and leptin-mutation-induced obesity.\",\n      \"method\": \"GWAS on thin individuals; RNAi-mediated knockdown of Alk in Drosophila (decreased triglyceride levels); genetic deletion of Alk in mice; measurement of energy expenditure and adipose tissue lipolysis\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic deletion with defined metabolic phenotype, replicated across two model organisms (Drosophila and mouse) with multiple metabolic measurements\",\n      \"pmids\": [\"32442405\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ALK fusions found in inflammatory myofibroblastic tumors (conventional and atypical) include TPM3/4-ALK, DCTN1-ALK, TFG-ALK, RANBP2-ALK, and a novel RRBP1-ALK fusion. RRBP1-ALK shows cytoplasmic ALK expression with perinuclear accentuation (distinct from the nuclear membranous pattern of RANBP2-ALK), demonstrating that fusion partner identity determines subcellular localization of ALK oncoprotein.\",\n      \"method\": \"ALK immunoprecipitation from tumor lysates; electrophoresis; mass spectrometry characterization of ALK fusion partners; immunohistochemistry for ALK localization\",\n      \"journal\": \"The Journal of Pathology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — ALK immunoprecipitation combined with mass spectrometry for partner identification and IHC for subcellular localization in a single rigorous study\",\n      \"pmids\": [\"27874193\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PTPN1 and PTPN2 phosphatases bind to ALK and regulate its phosphorylation and activity. Oncogenic ALK and STAT3 repress PTPN1 transcription (creating a feedback loop). PTPN1 is also a phosphatase for SHP2, a key mediator of oncogenic ALK signaling. Loss of PTPN1 or PTPN2 induces ALK TKI resistance by hyperactivating SHP2, MAPK, and JAK/STAT pathways.\",\n      \"method\": \"Genomic loss-of-function screens; Co-immunoprecipitation demonstrating PTPN1/PTPN2 binding to ALK; phosphatase activity assays; in vitro and in vivo resistance models; RNA sequencing of patient samples with TKI resistance; pharmacological combination of crizotinib with SHP2 inhibitor\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — genome-wide screen, Co-IP for binding, phosphatase activity assays, in vivo validation, and patient sample validation across multiple orthogonal methods\",\n      \"pmids\": [\"34657149\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"The SEC31A-ALK fusion transforms IL3-dependent Ba/F3 cells to growth factor independence, and the ALK inhibitor TAE-684 reduces cell proliferation and kinase activity of SEC31A-ALK and its downstream effectors ERK1/2, AKT, STAT3, and STAT5.\",\n      \"method\": \"Ba/F3 cell transformation assay; pharmacological inhibition with TAE-684; measurement of downstream effector phosphorylation (ERK1/2, AKT, STAT3, STAT5)\",\n      \"journal\": \"Haematologica\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional transformation assay with pathway analysis using inhibitor, single lab\",\n      \"pmids\": [\"20207848\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ALK signaling in neuroblastoma leads to phosphorylation of ATR and CHK1, supporting an effective DNA damage response. Combined ALK/ATR inhibition results in robust and sustained tumor response, whereas ATR inhibition alone yields initial response followed by relapse. The sustained response to combined inhibition reflects differentiation of tumor cells toward neuronal/Schwann cell lineage identity.\",\n      \"method\": \"Genetically modified mouse neuroblastoma models; biochemical measurement of ATR and CHK1 phosphorylation downstream of ALK signaling; in vivo treatment with ALK inhibitor, ATR inhibitor, and combination; lineage marker analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo mouse models with biochemical mechanistic validation, single lab\",\n      \"pmids\": [\"38154064\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ALKAL2 ligand overexpression drives ALK TKI-sensitive neuroblastoma in the absence of ALK mutation in mice, demonstrating that ligand-mediated (paracrine/autocrine) ALK activation is sufficient for neuroblastoma development and progression.\",\n      \"method\": \"Transgenic mouse model with ALKAL2 overexpression; ALK TKI treatment of resulting tumors; comparison with ALK mutation-driven models\",\n      \"journal\": \"The EMBO Journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic in vivo model with pharmacological validation, single lab\",\n      \"pmids\": [\"33411331\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ALK inhibitor resistance in ALK(F1174L)-driven neuroblastoma is associated with overexpression and activation of the AXL tyrosine kinase and epithelial-to-mesenchymal transition (EMT). AXL phosphorylation confers resistance through upregulated ERK signaling. AXL activation is mediated through increased expression of its ligand GAS6, which also stabilizes the AXL protein. AXL overexpression (but not TWIST2 overexpression alone) induces ALK inhibitor resistance.\",\n      \"method\": \"Generation of TAE684/LDK378-resistant neuroblastoma cell lines; Western blotting for AXL and downstream signaling; AXL inhibition studies; ectopic overexpression of AXL and TWIST2; GAS6 ligand analysis; HSP90 inhibitor studies\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic dissection with multiple orthogonal approaches (overexpression, inhibition, ligand analysis), single lab\",\n      \"pmids\": [\"26616860\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ALK positively regulates transcriptional expression of MYC and activates c-MYC transactivation of c-MYC target genes in ALK-positive NSCLC. MYCBP was identified as a determinant of crizotinib response by genome-wide shRNA screen, and inhibition of MYC by RNAi or small molecules sensitizes ALK+ cells to crizotinib.\",\n      \"method\": \"Whole-genome shRNA loss-of-function screen; RNAi knockdown of MYC; small-molecule MYC inhibition; transcriptional analysis of MYC target genes following ALK inhibition\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genome-wide screen with functional validation using two orthogonal approaches (RNAi and small molecule), single lab\",\n      \"pmids\": [\"29507657\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Pharmacological inhibition of ALK (by crizotinib or ceritinib) in ALK-positive ALCL induces immunogenic cell death (ICD), characterized by calreticulin surface exposure, ATP release, HMGB1 release, and type I interferon response. This ICD induction is on-target: it is mimicked by ALK knockdown, lost with resistance-conferring ALK mutants, and replicated by inhibiting downstream ALK signaling pathways. In vivo, ceritinib-treated ALK+ ALCL cells vaccinated immunocompetent mice and protected against rechallenge in an antigen-specific manner.\",\n      \"method\": \"ICD marker assays (calreticulin exposure, ATP/HMGB1 release); ALK siRNA knockdown; resistance-conferring ALK mutant cell lines; in vivo vaccination/rechallenge experiments in immunocompetent vs. immunodeficient mice; PD-1 blockade combination\",\n      \"journal\": \"Cell Death & Disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple ICD readouts, genetic validation with knockdown and mutants, in vivo immunological validation, single lab\",\n      \"pmids\": [\"34272360\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ALK inhibitors upregulate ALK expression on neuroblastoma cell surfaces while impairing tumor growth, thereby facilitating the activity of ALK-targeted CAR-T cells. The combination of ALK inhibitors with ALK.CAR-T cells shows potent efficacy specifically against neuroblastoma with low ALK expression, whereas neither modality alone is sufficient.\",\n      \"method\": \"ALK.CAR-T cell development and testing in vitro and in vivo; flow cytometry for ALK surface expression after inhibitor treatment; combination efficacy studies in neuroblastoma xenograft models\",\n      \"journal\": \"Cancer Cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic in vivo and in vitro studies demonstrating ALK inhibitor-induced antigen upregulation as the basis for combination synergy, single lab\",\n      \"pmids\": [\"38039964\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"PROTAC molecules (TD-004) composed of ceritinib (ALK inhibitor) linked to a VHL E3 ligase ligand effectively induce ALK fusion protein (NPM-ALK and EML4-ALK) degradation via the ubiquitin-proteasome system, inhibit growth of ALK fusion-positive cell lines, and significantly reduce tumor growth in H3122 xenograft models.\",\n      \"method\": \"PROTAC molecule design and synthesis; cell-based ALK degradation assays in SU-DHL-1 and H3122 cells; xenograft tumor growth assay\",\n      \"journal\": \"Biochemical and Biophysical Research Communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct protein degradation demonstrated in cells and in vivo with on-target mechanistic attribution via VHL-dependent pathway, single lab\",\n      \"pmids\": [\"30274779\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ALK is a receptor tyrosine kinase that, when activated via oncogenic fusions (e.g., NPM-ALK, EML4-ALK, TPM3/4-ALK) driven by dimerization through the N-terminal fusion partner, constitutively signals through multiple pathways including JAK/STAT3 (upregulating anti-apoptotic Bcl-xL and HIF1α), Ras/MEK/ERK, PI3K/AKT, and MYC; its subcellular localization is determined by the fusion partner, it directly binds IRS-1 to engage IGF-1R signaling and interacts with EGFR to activate AKT/IRF3/NF-κB in innate immune contexts, while the phosphatases PTPN1/PTPN2 restrain its activity by directly dephosphorylating ALK; in the nervous system, ALK is activated by ALKAL2 ligand and controls energy expenditure through hypothalamic neurons regulating adipose lipolysis, and in neuroblastoma it primes the DNA damage response via ATR/CHK1 phosphorylation.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ALK is a receptor tyrosine kinase that drives oncogenic transformation when its C-terminal kinase domain is fused to N-terminal partners that supply dimerization motifs, generating constitutively active fusion oncoproteins whose subcellular localization is dictated by the fusion partner [#1, #10]. In anaplastic large cell lymphoma and related malignancies, fusion proteins such as NPM-ALK, TPM3/4-ALK, and SEC31A-ALK signal through STAT3, ERK1/2, AKT, and STAT5; STAT3 activation is kinase-dependent and transcriptionally upregulates anti-apoptotic Bcl-xL and, via direct promoter binding, HIF1\\u03b1 [#0, #3, #12]. These fusions are sufficient to initiate and are required to maintain tumors, since genetic or pharmacological ALK inactivation drives sustained regression [#2]. ALK signaling also engages additional effectors: it binds the adaptor IRS-1 to couple into the IGF-1R pathway [#6], positively regulates MYC transcription and transactivation [#16], and its activity is restrained by the phosphatases PTPN1 and PTPN2, which directly bind and dephosphorylate ALK and limit SHP2-driven downstream signaling [#11]. Beyond fusion-driven cancers, point mutations in the ALK kinase domain constitutively activate the receptor in neuroblastoma [#7], where ligand-mediated activation by ALKAL2 is itself sufficient to drive tumorigenesis [#14] and ALK signaling supports an ATR/CHK1 DNA damage response [#13]. ALK additionally has non-oncogenic physiological and immune roles: it interacts with EGFR to activate AKT/IRF3/NF-\\u03baB and STING-dependent innate immunity in monocytes and macrophages [#8], and hypothalamic ALK controls energy expenditure and adipose lipolysis, with its loss conferring resistance to obesity [#9]. Resistance to ALK kinase inhibitors arises through secondary kinase-domain mutations, bypass activation of EGFR, IGF-1R, or AXL signaling, and loss of restraining phosphatases [#5, #6, #11, #15].\",\n  \"teleology\": [\n    {\n      \"year\": 2000,\n      \"claim\": \"Established that ALK becomes oncogenic by fusion of its kinase domain to partner-derived coiled-coil domains, generating constitutively active proteins whose localization tracks the partner.\",\n      \"evidence\": \"Molecular cloning, Western blot, and in vitro kinase assays of TPM3/4-ALK fusions in inflammatory myofibroblastic tumors\",\n      \"pmids\": [\"10934142\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the full downstream signaling cascade\", \"Limited to a single tumor type\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Resolved how fusion ALK signals for survival by showing kinase-dependent direct STAT3 phosphorylation upregulates anti-apoptotic Bcl-xL.\",\n      \"evidence\": \"Wild-type vs kinase-dead NPM-ALK K210R in BaF3 cells, inhibitor studies, and ALCL tissue immunohistochemistry\",\n      \"pmids\": [\"11850821\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Jak3 binding observed but dispensable, leaving the kinase upstream of STAT3 undefined\", \"Did not address other parallel pathways\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Demonstrated ALK fusions are both sufficient to initiate and required to maintain lymphoma, validating ALK as a therapeutic target.\",\n      \"evidence\": \"Conditional doxycycline-inducible transgenic mice with NPM-ALK and TPM3-ALK plus PF-2341066 inhibition\",\n      \"pmids\": [\"20223922\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not test fusion partners beyond NPM and TPM3\", \"Mechanism of regression not dissected at signaling level\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Extended ALK fusion signaling to transcriptional control of HIF1\\u03b1 via STAT3 binding to its promoter under normoxia.\",\n      \"evidence\": \"Kinase-dead mutant, ChIP, and STAT3/HIF1\\u03b1 siRNA in BaF3 and ALK+ TCL cells\",\n      \"pmids\": [\"21102525\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of HIF1\\u03b1-mediated mTORC1 suppression in vivo not established\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Showed additional fusions (SEC31A-ALK) transform cells and converge on ERK/AKT/STAT3/STAT5 effectors.\",\n      \"evidence\": \"Ba/F3 transformation assay with TAE-684 inhibition and downstream phospho-profiling\",\n      \"pmids\": [\"20207848\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single cell-line model\", \"No in vivo confirmation\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Defined two mechanisms of acquired resistance: a secondary kinase-domain mutation (L1152R) and EGFR bypass signaling, and showed dual inhibition overcomes both.\",\n      \"evidence\": \"Sequencing of patient-derived and engineered resistant cell lines with ALK/EGFR combination studies\",\n      \"pmids\": [\"21791641\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Prevalence of each mechanism in patients not quantified\", \"Other bypass pathways not surveyed\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Linked EML4-ALK fusion variant identity to differential inhibitor and HSP90 sensitivity through protein stability differences.\",\n      \"evidence\": \"Ba/F3 lines expressing v1/v2/v3a/v3b with cytotoxicity, localization, stability, and HSP90 combination assays\",\n      \"pmids\": [\"22912387\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Clinical correlation of variant-specific sensitivity not established\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identified IRS-1 as a direct ALK fusion partner coupling ALK to IGF-1R signaling and an inhibitor resistance pathway.\",\n      \"evidence\": \"Co-IP, IRS-1 siRNA, ALK/IGF-1R combination in resistant models, and patient biopsies\",\n      \"pmids\": [\"25173427\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Reciprocal validation of binding limited\", \"Stoichiometry of IRS-1 engagement unknown\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Distinguished oncogenic from non-oncogenic ALK kinase-domain mutations in neuroblastoma and tied them to differential crizotinib sensitivity.\",\n      \"evidence\": \"Genomic analysis of 1,596 neuroblastomas with biochemical kinase activity and crizotinib assays\",\n      \"pmids\": [\"25517749\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of inhibitor resistance per mutation not fully resolved\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Showed AXL/GAS6-driven EMT as a bypass resistance mechanism in ALK(F1174L) neuroblastoma.\",\n      \"evidence\": \"Resistant cell lines, AXL/TWIST2 overexpression, AXL inhibition, and GAS6 analysis\",\n      \"pmids\": [\"26616860\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"In vivo and patient confirmation of AXL resistance limited\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Cataloged diverse IMT fusion partners and reinforced that partner identity dictates ALK subcellular localization.\",\n      \"evidence\": \"ALK immunoprecipitation, mass spectrometry partner identification, and IHC localization including novel RRBP1-ALK\",\n      \"pmids\": [\"27874193\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional signaling differences between localization patterns not tested\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Revealed a non-oncogenic immune role: ALK interacts with EGFR to drive AKT/IRF3/NF-\\u03baB and STING-dependent innate immunity.\",\n      \"evidence\": \"Co-IP, ALK knockdown/knockout in monocytes/macrophages, and murine endotoxemia/sepsis models\",\n      \"pmids\": [\"29046432\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Direct ALK-EGFR binding not reciprocally validated\", \"Ligand or activation trigger in immune cells undefined\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Placed MYC downstream of ALK as a transcriptional effector and crizotinib-response determinant in NSCLC.\",\n      \"evidence\": \"Whole-genome shRNA screen, MYC RNAi and small-molecule inhibition, and MYC target transcriptional analysis\",\n      \"pmids\": [\"29507657\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Direct vs indirect transcriptional regulation not separated\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Connected ALK signaling to the DNA damage response via ATR/CHK1 phosphorylation and showed combined ALK/ATR inhibition drives lineage differentiation.\",\n      \"evidence\": \"Genetically modified mouse neuroblastoma models with biochemical phospho-readouts and lineage marker analysis\",\n      \"pmids\": [\"38154064\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Direct vs indirect ATR phosphorylation not resolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Demonstrated ALK fusion proteins can be eliminated by PROTAC-induced VHL-dependent degradation rather than catalytic inhibition.\",\n      \"evidence\": \"Ceritinib-VHL PROTAC (TD-004) degradation assays in SU-DHL-1/H3122 cells and H3122 xenografts\",\n      \"pmids\": [\"30274779\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Activity against resistant kinase-domain mutants not shown\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Defined a physiological role for ALK in hypothalamic control of energy expenditure and adipose lipolysis.\",\n      \"evidence\": \"GWAS in thin individuals, Drosophila RNAi, and Alk-deleted mice with energy expenditure and lipolysis measurements\",\n      \"pmids\": [\"32442405\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous ligand and downstream neuronal circuitry not fully mapped\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Showed ligand-mediated ALK activation by ALKAL2 is sufficient to drive neuroblastoma without ALK mutation.\",\n      \"evidence\": \"ALKAL2-overexpressing transgenic mice with ALK TKI treatment\",\n      \"pmids\": [\"33411331\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Relative contribution of autocrine vs paracrine ALKAL2 not resolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Established that ALK inhibition induces immunogenic cell death on-target in ALK+ ALCL, linking ALK targeting to anti-tumor immunity.\",\n      \"evidence\": \"ICD marker assays, ALK siRNA, resistance mutants, and in vivo vaccination/rechallenge in immunocompetent mice\",\n      \"pmids\": [\"34272360\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Generalizability beyond ALCL not tested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identified PTPN1/PTPN2 as direct ALK-binding phosphatases that restrain ALK and whose loss drives TKI resistance via SHP2 hyperactivation.\",\n      \"evidence\": \"Genome-wide LOF screens, Co-IP, phosphatase assays, in vivo resistance models, patient RNA-seq, and SHP2 inhibitor combination\",\n      \"pmids\": [\"34657149\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct dephosphorylation site mapping on ALK incomplete\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Showed ALK inhibitors upregulate surface ALK to enable ALK-targeted CAR-T efficacy against low-expression neuroblastoma.\",\n      \"evidence\": \"ALK.CAR-T development, flow cytometry for surface ALK after inhibitor treatment, and xenograft combination studies\",\n      \"pmids\": [\"38039964\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Mechanism of inhibitor-induced surface upregulation undefined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The structural basis by which ALKAL2 ligand and partner-driven dimerization activate the wild-type ALK ectodomain, and how endogenous ALK signaling is regulated across its physiological versus oncogenic contexts, remains incompletely defined.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model of ligand-bound full-length receptor in the corpus\", \"Endogenous ALK signaling outputs in normal neurons not mechanistically mapped\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 1, 3, 11]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 1, 7, 12]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [9, 14]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [9, 18]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [1, 10]},\n      {\"term_id\": \"GO:0005635\", \"supporting_discovery_ids\": [10]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 3, 6, 8, 12]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [1, 2, 5, 7, 10]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [8, 17]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [9]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [3, 16]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"IRS-1\", \"EGFR\", \"PTPN1\", \"PTPN2\", \"STAT3\", \"ALKAL2\", \"SHP2\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"tie","faith_supported":7,"faith_total":7,"faith_pct":100.0}}